Paul Tudor Jones’s Apellis Pharmaceuticals APLS Stock Holding History

Paul Tudor Jones’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,900	Closed	-$292K	–	3463
2025 Q3	$292K	Buy	+12,900	New	+$301K	﹤0.01%	2997
2025 Q2	–	Sell	-10,800	Closed	-$236K	–	3214
2025 Q1	$236K	Buy	10,800 +1,600	+17%	+$44.2K	﹤0.01%	2757
2024 Q4	$294K	Buy	+9,200	New	+$277K	﹤0.01%	2594

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Paul Tudor Jones's APLS Position: Q2 2026 in Review

Paul Tudor Jones sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 650,000 shares — an estimated $26.1M sold.

Paul Tudor Jones first reported a position in APLS in Q3 2020 and held it in 13 quarters. The position peaked at $26.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Paul Tudor Jones reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Paul Tudor Jones sold 650,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $26.1M.
Paul Tudor Jones first reported a position in Apellis Pharmaceuticals in Q3 2020 and held it in 13 quarters.
Paul Tudor Jones's Apellis Pharmaceuticals position peaked at $26.1M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.